Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01405651 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects
A Phase 1 study, sponsored by Ono Pharma USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01405651 is a Phase 1 study that has completed, run by Ono Pharma USA. The registered enrollment target is 24 participants.
The verdict
NCT01405651, a Phase 1 study, has completed, sponsored by Ono Pharma USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of ONO-6950 across ascending multiple doses in healthy adult male and female subjects. The secondary objectives are to characterize the PK and pharmacodynamic (PD) profiles of ONO-6950 by measuring plasma concentrations of ONO-6950 and pulmonary function.
Interventions
- DRUG ONO-6950
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01405651
The ClinicalTrials.gov registry entry for NCT01405651 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONO-6950 is the first listed.
NCT01405651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01405651 about?
NCT01405651 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects". The primary objective of this study is to evaluate the safety and tolerability of ONO-6950 across ascending multiple doses in healthy adult male and female subjects. The secondary objectives are to characterize the PK and pharmacodynamic (PD) profiles of ONO-6950 by measuring plasma concentrations o...
What is the current status of trial NCT01405651?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-07.
What interventions are being tested in trial NCT01405651?
The interventions under investigation include: ONO-6950 (DRUG).
Who is sponsoring clinical trial NCT01405651?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.